Efficiency of SARS-CoV-2 vaccines in breast cancer patients: single institutional experience from Institute for Oncology and Radiology of Serbia (IORS)
Annals of Oncology
; 33(Suppl. 3):S230-S230, 2022.
Article
in English
| GIM | ID: covidwho-2035757
ABSTRACT
Background:
Cancer patients are more sensitive to infection induced by SARS-CoV-2, especially ones with impaired immune response. Vaccines are approved as safe and effective, and they are recommended in oncology patients. The aim of our study was to see the percentage of reinfections after second dose of vaccines against SARS-CoV2.
human diseases; coronavirus disease 2019; viral diseases; pandemics; public health; efficacy; vaccines; vaccination; immunization; health protection; disease prevention; breast cancer; breast; neoplasms; immunocompromised hosts; patients; epidemiology; immune response; safety; dosage; reinfection; metastasis; drug therapy; risk reduction; pneumonia; lungs; respiratory diseases; mortality; disease course; immune sensitization; man; Severe acute respiratory syndrome coronavirus 2; Serbia; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; Balkans; Southern Europe; Europe; Mediterranean Region; upper-middle income countries; very high Human Development Index countries; SARS-CoV-2; viral infections; mammary tumour; cancers; breasts; Srbija; immunity reactions; immunological reactions; chemotherapy; lung diseases; death rate; disease progression
Full text:
Available
Collection:
Databases of international organizations
Database:
GIM
Topics:
Vaccines
Language:
English
Journal:
Annals of Oncology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS